ERBB2 and neoplasm: In other subgroup analyses (blinding and/or quality control, different ethnicity, various geographic region, ER status, HER-2 status, any tumor size, histological subtypes, and lymph node metastasis) and final sensitivity analyses (Figure 2), we found no association between p53 codon 72 polymorphism and BC risk.